Abstract
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
| Original language | English |
|---|---|
| Pages (from-to) | 820-827 |
| Number of pages | 8 |
| Journal | Cancer Investigation |
| Volume | 28 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Sep 2010 |
Fingerprint
Keywords
- Cisplatin
- Esophageal cancer
- Paclitaxel
- Preoperative chemoradiotherapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer : A phase II study. / Orditura, Michele; Galizia, Gennaro; Napolitano, Vincenzo; Martinelli, Erika; Pacelli, Roberto; Lieto, Eva; Aurilio, Gaetano; Vecchione, Loredana; Morgillo, Floriana; Catalano, Giuseppe; Ciardiello, Fortunato; Genio, Alberto Del; Martino, Natale Di; De Vita, Ferdinando.
In: Cancer Investigation, Vol. 28, No. 8, 09.2010, p. 820-827.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer
T2 - A phase II study
AU - Orditura, Michele
AU - Galizia, Gennaro
AU - Napolitano, Vincenzo
AU - Martinelli, Erika
AU - Pacelli, Roberto
AU - Lieto, Eva
AU - Aurilio, Gaetano
AU - Vecchione, Loredana
AU - Morgillo, Floriana
AU - Catalano, Giuseppe
AU - Ciardiello, Fortunato
AU - Genio, Alberto Del
AU - Martino, Natale Di
AU - De Vita, Ferdinando
PY - 2010/9
Y1 - 2010/9
N2 - We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
AB - We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50 significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
KW - Cisplatin
KW - Esophageal cancer
KW - Paclitaxel
KW - Preoperative chemoradiotherapy
UR - http://www.scopus.com/inward/record.url?scp=77956636233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956636233&partnerID=8YFLogxK
U2 - 10.3109/07357901003630926
DO - 10.3109/07357901003630926
M3 - Article
C2 - 20482249
AN - SCOPUS:77956636233
VL - 28
SP - 820
EP - 827
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 8
ER -